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The increasing prevalence of hospital and community-acquired infections caused by
multidrug-resistant (MDR) bacterial pathogens is limiting the options for effective antibiotic
therapy. Moreover, this alarming spread of antimicrobial resistance has not been paralleled
by the development of novel antimicrobials. Resistance to the scarce new antibiotics
is also emerging. In this context, the rational use of older antibiotics could represent
an alternative to the treatment of MDR bacterial pathogens. It would help to optimize
the armamentarium of antibiotics in the way to preserve new antibiotics and avoid the
prescription of molecules known to favor the spread of resistance (i.e., quinolones).
Furthermore, in a global economical perspective, this could represent a useful public
health orientation knowing that several of these cheapest “forgotten” antibiotics are
not available in many countries. We will review here the successful treatment of MDR
bacterial infections with the use of old antibiotics and discuss their place in current
practice.
Keywords: multi-drug-resistant pathogens, MRSA and VRE, ESBLs, colistin, fosfomycin, trimethoprim-
sulfamethoxazole combination, tetracycline, MDR-tuberculosis
INTRODUCTION
Antimicrobial resistance is one of the greatest threats to human
health worldwide (Walker et al., 2009). It dramatically reduces
the probability of effectively treating infections and increases the
morbidity and mortality associated with common bacterial dis-
eases (Klevens et al., 2007). Since the discovery of penicillin in
1928, antimicrobial resistance has been linked to antibiotic use.
Recent studies of bacteria in permafrost samples documented the
existence of resistance genes 30,000 years ago (D’Costa et al.,
2011), emphasizing that antibiotic use and misuse favor resis-
tance through selection pressure (Rolain et al., 2013). It has been
demonstrated that antimicrobial resistance prevalence can be
diminished through decreased antibiotic consumption (Seppälä
et al., 1997). This complex ecological phenomenon depends
on individuals, bacterial strains, and mechanisms of resistance
(Andersson and Hughes, 2010). Old and new antibiotics vary in
their impact on the emergence and spread of resistant bacteria
(Sullivan et al., 2001).
Bacterial strains resistant to newly developed antibiotics
have emerged recurrently (Long and Vester, 2012). Therefore,
antimicrobial resistance presents an ongoing challenge that
requires a multifaceted approach including (i) biomedical inno-
vation, (ii) improved surveillance of antibiotic consumption and
antimicrobial-resistance rates, (iii) prevention of health-care-
associated infections and transmission of multidrug-resistant
(MDR) bacteria and environmental dissemination, (iv) rapid
microbiological diagnosis, and (v) curtailed clinical and veteri-
nary misuse. It is alarming that although bacterial resistance
continues to emerge, the rate at which antibiotics are being
developed is decreasing. In this context, the reintroduction of
previously used antibiotics active against MDR bacteria repre-
sents a new alternative for the control of antimicrobial resistance
(Pulcini et al., 2012). As old antibiotics have rarely been subjected
to contemporary drug-development procedures or compared to
commonly used antibiotics, they are less considered in practice
guidelines. Therefore, their efficacy and safety must be revaluated
to optimize therapy.
This review aims at providing a non-exhaustive collection
of microbiological and clinical data on potentially useful older
antibiotics. We consider the value of “forgotten” antibiotics for
the treatment of (i) MDR Gram-negative bacterial infections
(polymyxins, fosfomycin, mecillinam, temocillin, and nitrofu-
rantoin); (ii) MDR Gram-positive infections [trimethoprim-
sulfamethoxazole (TMP/SMX), tetracyclines, chloramphenicol,
clindamycin, pristinamycin, rifampicin, and fusidic acid]; and
(iii) MDR tuberculosis (clofazimine, amoxicilline-clavulanate,
TMP/SMX, and minocycline).
FORGOTTEN ANTIBIOTICS FOR MULTIDRUG-RESISTANT
GRAM-NEGATIVE BACTERIA
The incidence of infections caused by MDR Gram-negative bac-
teria has increased worldwide over the last decade. The majority
of Escherichia coli and Klebsiella pneumoniae isolates reported by
European Antimicrobial Resistance Surveillance Network (EARS-
Net) in 2012 were resistant to at least one of the antimicrobials
tested, and many had combined resistance to third-generation
cephalosporins, fluoroquinolones, and aminoglycosides (http://
www.ecdc.europa.eu). Of particular importance to public health
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is the spread beta-lactamases with an extended spectrum, which
confer resistance to most β-lactams (even carbapenems for some
of them) and are frequently associated with resistance to other
groups of antibiotics in isolates of Enterobacteriaceae both from
community and health-care settings (Pitout and Laupland, 2008;
Zahar et al., 2009; Diene et al., 2013). In this context, it is essential
to optimize our antibacterial armamentarium. One major step
is to reconsider currently active and available antibiotics. Table 1
summarizes the successful clinical treatment of infections caused
by MDR Gram-negative bacteria with “forgotten” antibiotics,
either alone or in combination.
POLYMYXINS
Colistin, synthesized by Paenibacillus polymyxa subspecies col-
istinus, was discovered in 1949 (Komura and Kurahashi, 1979).
Polymyxin B and polymyxin E (colistin) are the 2 polymyxins
used in clinical practice. Their mechanism of action includes
attachment to the outer cell membrane of Gram-negative
Table 1 | Infections caused by multidrug-resistant Gram-negative bacteria successfully treated with old antibiotics.
Molecule Pathogens Sites of infection References
Colistin
(IV)
MDR A. baumannii
MDR P. aeruginosa
MDR K. pneumonia
MDR S. maltophilia
VAP
HA-pneumonia
UTI
IAI
BJI
Bacteremia
Wound infection
Meningitis
PJI
Diabetic foot infection
Jiménez-Mejías et al., 2002; Garnacho-Montero et al., 2003;
Linden et al., 2003; Markou et al., 2003; Fulnecky et al., 2005;
Kasiakou et al., 2005a,b; Falagas et al., 2006a,b; Motaouakkil
et al., 2006; Tascini et al., 2006; Kallel et al., 2007; Koomanachai
et al., 2007; Rios et al., 2007; Bassetti et al., 2008; Betrosian
et al., 2008; Mastoraki et al., 2008; Song et al., 2008; Tas¸bakan
et al., 2009; Kofteridis et al., 2010
Fosfomycin
(IV)
ESBL E. coli
ESBL
K. pneumonia/Enterobacter
sp./Serratia sp.
MDR P. aeruginosa
OXA-48 K. pneumonia and
E. coli
KPC K. pneumonia
Carbapenem-resistant P.
aeruginosa
MDR S. enterica serotype
Typhimurium
VAP
HA-pneumonia
UTI
IAI
BJI
Bacteremia
Wound infection
Meningitis
Brain abscess
Lung abscess
Cystic fibrosis (pulmonary
exacerbation)
Mirakhur et al., 2003; Nakaya et al., 2003; Michalopoulos et al.,
2010; Apisarnthanarak and Mundy, 2012; Dinh et al., 2012;
Karageorgopoulos et al., 2012; Navarro-San Francisco et al.,
2013; Pontikis et al., 2014
Fosfomycin
(PO)
ESBL E. coli and
K. pneumoniae
KPC K. pneumoniae
MDR P. aeruginosa
Lower UTI Pullukcu et al., 2007; Senol et al., 2010; Neuner et al., 2012
Pivmecillinam
Mecillinam
(PO)
ESBL E. coli and
K. pneumonia
CTX-M/ESBL E. coli
ESBL Enterobacteriaceae
Lower UTI
Relapsing pyelonephritis
Complicated UTI
Nicolle and Mulvey, 2007; Titelman et al., 2012; Jansåker et al.,
2014; Søraas et al., 2014
Temocillin
(IV)
dAmpC/ESBL
Enterobacteriaceae
ESBL E. coli and
K. pneumonia
MDR P. agglomerans
HA pneumonia
UTI
Bacteremia
Severe sepsis (VAP, UTI, IAI)
Epidural abscess
Subacute synovitis
Barton et al., 2008; Duerinckx, 2008; Gupta et al., 2009;
Balakrishnan et al., 2011
Nitrofurantoin
(PO)
ESBL E. coli Lower UTI Tasbakan et al., 2012
MDR, Multidrug-resistant; P. aeruginosa, Pseudomonas aeruginosa; A. baumanii, Acinetobacter baumanii; E. coli, Escherichia coli; K. pneumonia, Klebsiella pneu-
moniae; S. enterica, Salmonella enterica; P. agglomerans, Pantoea agglomerans; VAP, Ventilator-associated pneumonia; HA, Hospital-acquired; UTI, Urinary-tract
infection; BJI, Bone and joint infection; PJI, Prosthetic-joint infection; IAI, Intra-abdominal infection; ESBL, Extended-spectrum β-lactamases; IV, Intravenous; PO,
Per os.
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bacteria, leading to membrane-permeability changes and cell
death. Colistin was initially used in Japan and in Europe dur-
ing the 1950s and was used in the United States in the form of
colistimethate sodium in 1959 (Reed et al., 2001). Intravenous
formulations of colistin and polymyxin B were gradually aban-
doned in most parts of the world in the early 1980s because of the
reported high incidence of nephrotoxicity (Biswas et al., 2012).
Indeed, most of the drug is excreted in the urine, and dose adjust-
ment is required in patients with renal failure. Recent studies
have shown that better management of intravenous formulations
led to considerably less toxicity than was reported in old studies
(Falagas and Kasiakou, 2005). Inhaled colistin has been proposed
as alternative, in adjunction to systemic therapy or alone, for the
treatment of pneumonia or chronic lung infection with MDR
Gram-negative bacteria (Lu et al., 2012; Tumbarello et al., 2013).
Although promising results have been reported, more data are
needed to establish its appropriate role in mechanically-ventilated
patients (Michalopoulos and Falagas, 2014).
Colistin was recommended by the most recent American
Thoracic Society Guidelines as a therapeutic option for the
treatment of ventilator-associated pneumonia (VAP) caused by
MDR Gram-negative organisms (American Thoracic Society,
and Infectious Diseases Society of America, 2005). Intravenous
polymyxins has been evaluated for the treatment of serious MDR
P. aeruginosa, Acinetobacter baumannii and Enterobacteriaceae
infections of various types, including pneumonia, bacteremia,
abdominal infections, bone and joint infections (BJIs), urinary-
tract infections (UTIs), and meningitis (Falagas and Kasiakou,
2005) (Table 1).
One worrisome problem is the emergence of colistin resis-
tance in KPC-producing bacteria, as seen in up to 20% of isolates
in some countries (Kontopidou et al., 2014). The spread of col-
istin resistance may be related to the extensive use of this drug
in empiric and targeted treatment and also due to the ecologi-
cal effect of topical use in selective decontamination protocols in
intensive-care units (Oostdijk et al., 2013). But, themost common
mechanism of colistin resistance is modification of LPS (Park
et al., 2011). As it chromosomal, it is not prone to spread hori-
zontally, but relies exclusively on clonal expansion. Several other
mechanisms have been suggested, most of which involve changes
in the outer membrane (Li et al., 2006). Paenibacillus polymyxa
subspecies colistinus, also produces colistinase, which inactivates
colistin. However, enzymatic resistance of bacteria to colistin has
not been reported in clinical practice (Falagas and Kasiakou,
2005). Interestingly, decades of colistin use in veterinary medicine
has not been associated with an increased resistance prevalence in
commensal Escherichia coli isolated from animals (Wasyl et al.,
2013). Regarding Acinetobacter baumanii, colistin resistance has
emerged worldwide (Cai et al., 2012). Although it associated with
impaired virulence (Rolain et al., 2011), combination therapy
might be the best antimicrobial strategy. Besides, optimization
of colistin use should prevent the emergence of species naturally
resistant to colistin, such as S. marcescens and P. mirabilis, which
have the potential to cause outbreaks (Merkier et al., 2013).
FOSFOMYCIN
Fosfomycin is an antimetabolite inhibitor that prevents the
formation of N-acetylmuramic acid, an essential precursor of
peptidoglycan-chain formation in the bacterial wall. It was first
identified in Spain in 1969 in the fermentation broths of sev-
eral strains of Streptomyces sp. (Raz, 2012). Fosfomycin has a
broad spectrum of antimicrobial activity, including a rapid bac-
tericidal effect against several Gram-negative and Gram-positive
aerobic bacteria (Falagas et al., 2009). Unlike many alternatives,
fosfomycin formulations are generally well tolerated, with mini-
mal toxicity (excepting thrombophlebitis when administered via
peripheral venous catheter).
The use of intravenous fosfomycin formulations for the treat-
ment of infections caused by MDR bacteria has shown a high rate
of clinical success (Table 1). For lower UTIs, the successful use of
oral fosfomycin tromethamine is well documented.
One of the first studies on the broad use of fosfomycin in
Spain noted development of resistance in 3% of the 959 cases
in total but in 10% of the 86 P. aeruginosa infections (Rodríguez
et al., 1977). These rates of emergence appear to be stable over
time in countries where fosfomycin use has been used for decades
(Falagas et al., 2008). But, fosfomycin resistance is in many
bacterial species caused by plasmid-mediated fosfomycin genes
(Suárez and Mendoza, 1991). Currently, plasmid-mediated fos-
fomycin resistance determinants, have been discovered and are
related to fosfomycin resistance in Escherichia coli (fosA, fosA3,
fosC) (Lee et al., 2012), Enterobacter cloacae (fosA2) (Xu et al.,
2011), Klebsiella pneumoniae (fosA, fosA3) (Lee et al., 2012),
Staphylococcus spp. (fosB) (Suárez and Mendoza, 1991), and,
Enterococcus faecium (fosB3) (Xu et al., 2013). Chromosomally
resistant mutants have also been well described (Suárez and
Mendoza, 1991). This is a major concern about the potential for
the selection and spread of resistance. Then, when used to treat
systemic infections, intravenous fosfomycin may be a component
of combination therapy administered (Pogue et al., 2011).
PIVMECILLINAM/MECILLINAM
Pivmecillinam is the prodrug of mecillinam, a unique β-lactam
with high specificity against penicillin-binding protein 2 (PBP-
2) in the Gram-negative cell wall and therefore is highly active
against Enterobacteriaceae and resistant to β-lactamases. This
drug for oral use is well tolerated and can be given in patients with
impaired renal function, but its usefulness is limited by its lack
of activity against Gram-positive organisms and Pseudomonas
aeruginosa (Dewar et al., 2014). Since its introduction in the
1970s, it has been widely used for the treatment of acute lower
UTIs, primarily in the Nordic countries (Graninger, 2003).
Treatment of lower UTIs caused by ESBL-producing E. coli
has produced variable results (Titelman et al., 2012; Poulsen
et al., 2013; Søraas et al., 2014) (Table 1). The high rates of
treatment failure (44%) reported by Søraas et al. raised con-
cerns regarding the optimal dosing that suggest the need for
further studies (Søraas et al., 2014). Treatment with pivmecilli-
nam was successful in a case of relapsing pyelonephritis caused by
ESBL-producing E. coliwhere other treatments had failed (Nicolle
and Mulvey, 2007). Currently, the use of pivmecillinam as first-
line treatment for uncomplicated UTIs is recommended by the
Infectious Diseases Society of America and the European Society
for Microbiology and Infectious Diseases (Gupta et al., 2011).
The widespread and long-term use of pivmecillinam for UTIs
in Scandinavian countries is well documented, with no indication
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of any significant increase in mecillinam resistance in these coun-
tries (Graninger, 2003). Indeed, Pivmecillinam is a prodrug and
thus has a low impact on the endogenous microflora (Sullivan
et al., 2001). Although poorly studied, mecillinam resistance have
been shown to be caused by mutations in the genes affecting the
elongation process of the bacteria, and associated with substan-
tial fitness cost in vitro to the resistant E. coli (Wachi et al., 1987).
These properties lead to a decreased potential for the selection of
resistance.
TEMOCILLIN
Developed and first marketed in the UK in the 1980s, temocillin
was quickly abandoned because its lack of activity against Gram-
positive organisms, anaerobes and Pseudomonas aeruginosa was
perceived as a major limitation (Slocombe et al., 1981). This beta
lactam antibiotic, that is the 6-α-methoxy derivative of ticarcillin,
is also characterized by its resistance to most beta-lactamases
with an extended spectrum (i.e., TEM, SHV, CTX-M, AmpC)
and some carbapenemases (Livermore et al., 2006; Rodriguez-
Villalobos et al., 2006; Glupczynski et al., 2007; Adams-Haduch
et al., 2009). Temocillin is mainly excreted renally and therefore
requires dosage adjustment in patients with renal impairment.
Based on temocillin’s relatively narrow spectrum, it is appro-
priate for use in microbiologically directed therapy, particularly
for the UTIs caused by confirmed ESBL producers. In this set-
ting, temocillin might be used as an alternative to carbapenems
(Livermore and Tulkens, 2009), as temocillin is ecologically safer.
Research in Belgium suggests that temocillin is also effective in
severe infections such as VAP if the organism appears susceptible
in vitro (De Jongh et al., 2008). It is also a potential alter-
native treatment option for mild-to-moderate UTIs caused by
KPC-producing Enterobacteriaceae (Adams-Haduch et al., 2009).
The first reported case of breakthrough bacteremia during
temocillin treatment occurred in a patient with renal dysfunc-
tion and probable insufficient dosing (1 g once daily) (Gupta
et al., 2009). NDM-1 and OXA-48 carbapenemases also confer
resistance to temocillin (Livermore et al., 2011). Although poorly
studied, the main mechanisms of resistance to temocillin are effi-
cient efflux or reduced PBP binding that could explain highMICs
to Pseudomonas aeruginosa (Livermore and Tulkens, 2009).
NITROFURANTOIN
Nitrofurantoin (NFT), which is a synthetic antimicrobial derived
from furan by the addition of a nitro group and a side chain
containing hydantoin, was introduced into clinical practice in
its microcrystalline form in 1952. Since the macrocristalline
form was developed, the previously frequent gastrointesti-
nal side effects have become less common, giving this drug
a good safety profile (Cunha, 1989). This molecule has a
broad-spectrum activity against the main uropathogens (i.e.,
Escherichia coli, Citrobacter species, group-B streptococci, entero-
cocci, Staphylococcus aureus, S. epidermidis, Klebsiella pneumonia,
and Enterobacter sp.) and has also been shown to be active against
ESBL-producing Enterobacteriaceae and vancomycin-resistant
enterococci. Notably, it lacks activity against Pseudomonas aerug-
inosa, Serratia marscecens, and Proteus mirabilis (Cunha et al.,
2011).
NFT is effective both in vitro and in clinical studies against
ESBL-producing E. coli (Table 1); however, given that patients
with acute pyelonephritis respond inconsistently to NFT and that
bacteremia has occurred during NFT treatment, its use has been
restricted to lower UTIs (Tasbakan et al., 2012). Currently, NFT
is recommended as a first-line treatment for uncomplicated UTIs
by the Infectious Diseases Society of America and the European
Society for Microbiology and Infectious Diseases (Gupta et al.,
2011).
Recent surveys have found a persistent low prevalence of resis-
tance to NFT (1.9–7.7%) among urinary E. coli isolates, including
those resistant to TMP/SMX or ciprofloxacin; the prevalence of
this resistance reaches 23.2% in ESBL-producing E. coli (Tasbakan
et al., 2012). Chromosomally resistance-conferring mutations
have been identified in the nsfA and nsfB genes that encode
oxygen-insensitive nitroreductases, and associated with substan-
tial fitness cost in vitro to the resistant E. coli (Sandegren et al.,
2008). These properties lead to a decreased potential for the
selection of clinically relevant resistance.
FORGOTTEN ANTIBIOTICS FOR MULTIDRUG-RESISTANT
GRAM-POSITIVE BACTERIA
Staphylococcus aureus and Enterococcus spp. are two of the most
common organisms causing nosocomial infections and are con-
sistently associated with high mortality rates (Pea and Viale,
2007). Resistance among these pathogens to first-line agents such
as methicillin and vancomycin continues to rise, while isolates
with reduced susceptibility to newer agents, including linezolid,
are also emerging (Patel et al., 2013). In Table 2, we summarized
the successful clinical treatment of infections caused by MDR
Gram-positive bacteria with “forgotten” antibiotics alone or in
combination.
TRIMETHOPRIM-SULFAMETHOXAZOLE
The combination drug TMP/SMX acts as a broad-spectrum
bactericidal agent and was introduced clinically in the early
1970s (Grim et al., 2005). Trimethoprim is a tetrahydrofolate
reductase inhibitor that, when added to sulfamethoxazole, pro-
vides a second-step block in the folate biosynthetic pathway
(Proctor, 2008). According to its good oral bioavailability, high-
dosage regimen of TMP/SMX represents a suitable alternative for
methicillin-resistant S. aureus (MRSA) infections (Muhammed
Ameen et al., 2014).
TMP/SMX is recommended as first-line treatment for
uncomplicated UTIs, skin and soft-tissue infections (SSTIs),
and community-associated methicillin-resistant Staphylococcus
aureus (CA-MRSA) infections, according to clinical practice
guidelines (Gupta et al., 2011; Stevens et al., 2014). In a recent
study with a cohort of 328 patients with infections due to MRSA
with a MIC to vancomycin of 2μg/mL, TMP/SMX alone com-
pared favorably to linezolid and daptomycin in terms of treatment
efficacy, mortality, and reduced antibiotic costs (Campbell et al.,
2012). Although TMP/SMX alone has been shown to be less
effective than current treatment for MRSA endocarditis (i.e.,
vancomycin or teicoplanin) (de Górgolas et al., 1995), in com-
bination with other antibiotics (i.e., daptomycin, clindamycin
or vancomycin, and rifampicin) successful treatments have been
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Table 2 | Infections caused by multidrug-resistant Gram-positive bacteria successfully treated with old antibiotics.
Molecule Pathogens Sites of infection References
Trimethoprim-
sulfamethoxazole
(TMP/SMX)
(IV, PO)
CA and HA-MRSA
E. americana
SSTI
BJI
Osteomyelitis
IE (prosthetic valve)
Meningitis
Bacteremia
COPD exacerbation
Shafqat et al., 1971; Seligman et al., 1973; Bengtsson et al., 1974; Tamer
and Bray, 1982; Levitz et al., 1984; Stein et al., 1998; Cenizal et al., 2007;
Pound et al., 2007; Nguyen et al., 2009; Goldberg et al., 2010; Cadena
et al., 2011; Messina et al., 2011; Di Carlo et al., 2013
Minocycline
(IV, PO)
MRSA SSTI
BJI
Osteomyelitis
IE (prosthetic valve)
Bacteremia
Clumeck et al., 1984; Lawlor et al., 1990; Moreno et al., 1994; Ruhe
et al., 2005; Cenizal et al., 2007; Ruhe and Menon, 2007
Doxycycline
(IV, PO)
MRSA
VREf
SSTI
UTI
Bacteremia
Chloramphenicol
(IV)
VRE
VREf
S. maltophilia
Meningitis
Ventriculitis
Bacteremia
IAI
EI (prosthetic valve)
Norris et al., 1995; Lautenbach et al., 1998; Pérez Mato et al., 1999;
Mehta et al., 2000; Ricaurte et al., 2001; Scapellato et al., 2005
Clindamycin
(IV, PO)
MRSA
MRSA (PVL+)
SSTI
BJI
Mandible osteomyelitis
Necrotizing fasciitis
Necrotizing pneumonia
Bacteremia
Martínez-Aguilar et al., 2003; Hidron et al., 2009; Tobeña Rué et al.,
2009; Tuzuner-Oncul et al., 2009; Kefala-Agoropoulou et al., 2010
Pristinamycin
(PO)
MRSA
VRE
CoNS
Pneumonia
SSTI
UTI
BJI
Epidural abscess
Dancer et al., 2003; Ng and Gosbell, 2005; Ruparelia et al., 2008; Reid
et al., 2010
Fusidic acid
(PO)
MRSA BJI
PJI
Chronic osteomyelitis
Epidural abscess
Nather et al., 2005; Howden and Grayson, 2006; Aboltins et al., 2007;
Murray et al., 2008; Ahamed Puthiyaveetil, 2009; Ferry et al., 2010;
Chiang et al., 2011; O’Neill et al., 2011; Wolfe, 2011
Nitrofurantoin
(PO)
VREf Chronic prostatitis Taylor et al., 1998
Fosfomycin
(PO)
VREf Lower UTI Neuner et al., 2012
Fosfomycin
(IV)
MRSA
CoNS
Meningitis
IE
PJI
De Boutin et al., 1985; Roualdes et al., 1985; Silbermann et al., 1995;
Lee et al., 2013
MRSA, methicillin-resistant Staphylococcus aureus; CA, community-associated; CoNS, coagulase-negative Staphylococci; VRE, vancomycin-resistant Enterococcus
sp.; VREf, vancomycin-resistant Enterococcus faecium; S. maltophilia, Stenotrophomonas maltophilia; VAP, ventilator-associated pneumonia; IE, infective endocardi-
tis; UTI, urinary-tract infection; BJI, bone and joint infection; PJI, prosthetic-joint infection; IAI, intra-abdominal infection; IV, Intravenous; PO, Per os.
reported (Fujino et al., 2009; Casalta et al., 2013; Di Carlo et al.,
2013). Only one randomized, prospective trial compared TMP-
SMZ to vancomycin for the treatment of S. aureus (47% MRSA)
endovascular infections in injection-drug users. In this study,
TMP-SMZ was inferior to vancomycin only for the treatment of
methicillin-susceptible S. aureus (MSSA), while the cure rates and
other clinical and microbiological outcomes against the MRSA
group were similar for both drugs (Markowitz et al., 1992).
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Long-term oral ambulatory treatment with TMP-SMZ appeared
to be an effective alternative to the conventional medicosurgical
treatment of chronic MDR Staphylococcus sp.-infected orthope-
dic implants (Stein et al., 1998). The scarcity of data concerning
TMP-SMZ treatment for S. aureus infections emphasizes the need
for further clinical studies comparing this drug to other available
options, specifically vancomycin (Adra and Lawrence, 2004).
Over a 10-year period, interrupted time-series analysis demon-
strated that the CA-MRSA period was associated with a
significant increase in use of TMP/SMX but showed no sig-
nificant changes in the rates of susceptibility among clinical
isolates. There was also no evidence for selection of organ-
isms with increased resistance to other antimicrobials in relation
to increased TMP-SMZ use (Wood et al., 2012). Moreover, a
recent report has shown high rates of susceptibility to TMP-
SMZ (94%) in community-acquired MRSA (CA-MRSA) isolates
(Chen et al., 2006). In another study, all 320 isolates of MRSA
(97% of USA300 strain) from outpatients with SSTIs were sus-
ceptible to TMP/SMZ (Moran et al., 2006). But this drug has
also been considered to favor the selection and spread of resistant
microorganisms on a population level. One study found that the
mechanism was the selection for a class 1 integron, resulting in
MDR Enterobacteriaceae in the intestinal flora of children (Van
der Veen et al., 2009). Knowing that integrons are transferable
genetic elements capable of expressing multiple resistance genes,
the use of TMP-SMZ should be cautiously monitored regarding
this potential collateral damage.
TETRACYCLINES
Chlortetracycline, from which tetracycline was derived in 1953,
is produced by Streptomyces aureofaciens. In the late 1960s, the
second-generation long-acting compounds doxycycline (in 1966)
and minocycline (in 1967) were semi-synthetically derived and
commercialized. Tetracyclines are a class of broad-spectrum bac-
teriostatic antibiotics active against Gram-positive and Gram-
negative bacteria, as well as against intracellular organisms. These
characteristics, together with the low cost and rarity of major
side effects, have made tetracyclines a widely used class of antibi-
otics (Nelson and Levy, 2011). However, it should be noted that
these drugs are contraindicated in pregnant woman, neonates,
and young children because of their particular effects on skeletal
growth and dentition (Demers et al., 1968).
Tetracyclines have been evaluated as an effective oral treat-
ment option for patients with SSTIs caused by MRSA (Ruhe and
Menon, 2007). Minocycline, associated with surgical drainage,
resulted in rapid resolution of MRSA-associated cutaneous
abscesses (Cunha, 2013). Doxycycline has intrinsic activity
against enterococci, including VRE, and has been stated as an
option for oral treatment of VRE cystitis (Heintz et al., 2010).
Bacteremia caused by VRE has been successfully treated with
doxycycline (Moreno et al., 1994).
Recently, a MDR strain of CA-MRSA genotype USA300 has
emerged, with plasmids that confer resistance to tetracycline,
macrolides, and clindamycin (Diep et al., 2008). Staphylococcal
resistance to tetracyclines is mainly conferred by active reflux,
which is mediated by plasmid-located tetK and tetL genes, and
ribosomal protection, which is mediated by chromosomal or
transposonal tetM or tetO genes (Trzcinski et al., 2000). Studies
relating the MICs of tetracycline, doxycycline, and minocycline
to the presence of these genes suggest a crossresistance between
doxycycline and tetracycline in all strains of S. aureus whereas
minocycline could be in few cases spared. Caution is therefore rec-
ommended in the use of tetracyclines, given its ability to induce
resistance in areas in which strains carry the inducible resistance
genes (Schwartz et al., 2009). Besides, long-term use of tetracy-
clines in veterinary medicine has been associated with resistance
emergence in commensal Escherichia coli in veal calves (Bosman
et al., 2014).
CHLORAMPHENICOL
Chloramphenicol, the active compound of which is produced
by Streptomyces venezuelae, inhibits protein synthesis by bind-
ing reversibly to the 50S subunit of the bacterial ribosome. It
is metabolized primarily in the liver. Dose adjustment is thus
required in patients with hepatic insufficiency. Furthermore,
chloramphenicol has good oral bioavailability and excellent tis-
sue penetration. Its spectrum of activity is broad, including
Gram-positive and Gram-negative bacteria, anaerobes, spiro-
chetes, rickettsiae, chlamydiae, and mycoplasma. But, soon after
chloramphenicol was released in the United States in 1949,
reports linked this drug to rare but potentially lethal hemato-
logical side effects that restricted its use as last-resort therapy.
However, as it is readily available and inexpensive, it is still used
in many resource-limited settings (Falagas and Kopterides, 2007).
Further studies are needed to update its toxicity risk with more
accurate dosing and monitoring (Lautenbach et al., 1998).
Chloramphenicol was found to be effective against
vancomycin-resistant Enterococcus faecium (VREf ), with
bacteriostatic activity (Norris et al., 1995). A retrospective
analysis of the outcomes of six patients with bacteremia caused
by VREf also showed that this agent was effective (Ricaurte
et al., 2001). Several anecdotic reports of effective treatment
with chloramphenicol in MDR bacterial severe infections been
reported (Table 2).
Of 697VRE samples from 28 US medical centers, only
2.4% were resistant to chloramphenicol (Zhanel et al., 2003).
A significant decrease in rates of resistance to chlorampheni-
col among isolates of enterococci was reported from 2006
to 2009 in a Brazilian monocentric survey (Conceição et al.,
2011). According to the SENTRY Antimicrobial Surveillance
Program, the rate of chloramphenicol resistance among E. fae-
calis is greater in North America than in Europe (28.6 vs. 7.1%,
respectively), but the reverse is true of E. faecium (0.5 and
15%, the latter due to clonal occurrences) (Deshpande et al.,
2007). Chloramphenicol use for the treatment of VRE infec-
tions should take into account the potential for the development
of resistance (Lautenbach et al., 2004). Indeed, high levels of
resistance likely due to the widespread and unregulated use in
resource-limited settings have been reported, particularly for the
treatment of severe disease caused by MDR Salmonella sp. or
VREf. Most resistance mechanisms are efflux pumps such as
floR and cmlA, as well as inactivating enzymes such as chlo-
ramphenicol acetyl-transferase cat1 (Frye and Jackson, 2013).
Furthermore, the association between fluoroquinolone use and
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chloramphenicol-resistant VRE emergence is of concern, since
fluoroquinolone use has dramatically increased in recent years
(Gould et al., 2004).
CLINDAMYCIN
Clindamycin is produced by chemical modification of lin-
comycin, which was isolated in 1962 from Streptomyces lincol-
nensis (McGehee et al., 1968). This drug works by binding to
the 50S ribosomal subunit of rRNA and inhibiting the initiation
of peptide-chain synthesis. Although concern about Clostridium
difficile colitis has limited the use of clindamycin, it remains
an important antibiotic in the treatment of severe anaerobic
infections.
The main advantage of clindamycin is its potential anti-
exotoxin activity in necrotizing Panton-Valentin leucocidin
(PVL)-positive CA-MRSA-complicated pneumonia or SSTIs, and
it is usually used with another anti-MRSA antibiotic (Hidron
et al., 2009). Clindamycin is also recommended by clinical prac-
tice guidelines as monotherapy for CA-MRSA SSTIs (Stevens
et al., 2014).
Among 320 isolates of MRSA (97% of USA300 strain) from
outpatients with SSTIs, 95% were susceptible to clindamycin
(Moran et al., 2006). In another study, 98% of CA-MRSA iso-
lates from patients with SSTI, were susceptible to clindamycin
(Ruhe et al., 2007). Conversely, in Taiwan, a recent study found
that nearly 96% of MRSA isolates from patients with necrotiz-
ing fasciitis were resistant to clindamycin. In a recent micro-
biological survey of CA-MRSA, 72 isolates (85% of European
ST80 clone) from children with severe infections in Greece, clin-
damycin resistance increased significantly from 0% (2003) to
31.2% (2009) among the CA-MRSA isolates (Katopodis et al.,
2010).This increase suggests clonal diversity in clindamycin sus-
ceptibility among MRSA strains that calls for direct surveillance
and reports (Changchien et al., 2011). Moreover, inducible clin-
damycin resistance should be ruled out by a D-test because a sub-
stantial proportion of erythromycin-resistant isolates have shown
clindamycin resistance despite appearing susceptible on initial
testing (Siberry et al., 2003). Indeed, resistance genes confer resis-
tance to macrolides, lincosamides, streptogramins (MLS). They
cause resistance mainly by (i) target site modification, (ii) efflux
pumps, and (iii) enzymatic inactivation. But new conjugative
transposons (mobile genetic elements) carrying MLS genes along
with other antibiotic resistance genes have recently been identi-
fied favoring the horizontal spread of resistance (Roberts, 2008).
Thus, clindamycin should be used in combination with another
anti-staphylococcal antibiotic as empiric therapy in patients with
suspected severe staphylococcal infections.
PRISTINAMYCIN
Pristinamycin, derived from Streptomyces pristinaespiralis, is an
oral streptogramin antibiotic made up of two synergistic but
structurally unrelated components, pristinamycin IA and pristi-
namycin IIA. It was discovered over 50 years ago (Cooper et al.,
2014).
Although the data are limited, pristinamycin is a well-tolerated
and effective alternative for the treatment of BJI due to Gram-
positive bacteria including MRSA and VRE (Dancer et al., 2003;
Ng and Gosbell, 2005; Ruparelia et al., 2008; Reid et al., 2010).
The extended use of pristinamycin for BJI and other infections
requires further evaluation.
Many enterococcal species, including those that are
vancomycin-resistant though not including Enterococcus
faecalis, are also susceptible to pristinamycin (Collins et al.,
1993). In France, resistance to pristinamycin has remained low
over the last 40 years, and typical susceptibility rates amongst
staphylococci are 98% in the community (Quentin et al., 2001)
and 93% in hospitals (Leclercq et al., 2003). But, also concerned
by MLS resistance genes, the use of pristinamycin could favor the
horizontal spread of resistance.
RIFAMPICIN
Rifampicin is a semi synthetic compound derived from
Streptomyces mediterranei. It was introduced in 1967 asmajor part
of the anti-tuberculous treatment. Rifampicin has an excellent
tissue penetration and a unique activity on bacteria in biofilms
growing on the surface of prosthetic devices. Despite the excel-
lent bactericidal activity and oral bioavailability, the rapid emer-
gence of resistance in bacteria constitutes a major limitation and
therefore rifampicin should be used in combination with other
antimicrobial agents. The cause of rifampicin-resistant mutations
within bacteria are due to alteration in the rpoB gene (Forrest and
Tamura, 2010).
Despite the lack of a control group and the limited number of
patients, colistin and rifampicin appeared to be an effective and
safe combination therapy for severe infections caused by MDR
Acinetobacter baumanii (Motaouakkil et al., 2006; Bassetti et al.,
2008) or MDR Pseudomonas aeruginosa (Tascini et al., 2006).
Rifampicin with fusidic acid or rifampicin with fluoroquinolones
treatment has been shown to be effective, in combination with
surgical debridement, on early prosthesis joint infections (PJI)
caused by MRSA (Aboltins et al., 2007). But combination ther-
apy with rifampicin for the treatment of severe MRSA infections
needs further studies (Forrest and Tamura, 2010).
FUSIDIC ACID (FA)
Fusidic acid, which is derived from the fungus Fusidium
coccineum, was introduced into clinical practice in 1962
(Godtfredsen et al., 1962). It inhibits polypeptide-chain elonga-
tion by binding to the ribosome elongation factor G (EF-G)–GDP
complex. FA has excellent oral bioavailability and is metabolized
and excreted by the liver. The action of FA is mainly bacteriostatic
against Gram-positive bacteria, but this drug has bactericidal
activity at higher concentrations. Notably, FA has only limited
activity against streptococci and enterococci. It is highly protein-
bound and has been shown to have good concentrations in soft
tissue, bone and synovial fluid (Turnidge, 1999).
Although there have been no randomized controlled trials of
FA as a treatment for BJIs due to MRSA, several case series have
reported its effectiveness, mostly in combination with another
oral antibiotic (Drancourt et al., 1997; Aboltins et al., 2007; Ferry
et al., 2010).
Rates of resistance to FA are higher among coagulase-negative
staphylococci (CoNS) than among S. aureus isolates (Pfaller et al.,
2010). Although the rate of in vitro resistance to FA among
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S. aureus is less than 10% in most countries (Wang et al., 2012),
there is also a significant trend toward increased FA resistance
associated with its increased use (Castanheira et al., 2010). For
instance, in Kuwait, the rate of FA resistance increased dramat-
ically from 22% in 1994 to 92% in 2004 (Udo et al., 2006).
High usage of topical fusidic acid has been associated with clonal
spread of fusidic acid-resistant Staphylococcus aureus (Williamson
et al., 2014). Key resistance determinants include mutations in
the fusA gene, which encodes EF-G, and plasmid-mediated resis-
tance (i.e., acquisition of resistance gene fusB) (Howden and
Grayson, 2006). Therefore, this agent must be used in combina-
tion with rifampin or other agents to prevent the emergence of
resistance.
FORGOTTEN ANTIBIOTICS FOR MULTIDRUG-RESISTANT
M. TUBERCULOSIS
Tuberculosis strains classified as MDR are those resistant to at
least the two most potent first-line antituberculosis drugs (i.e.,
isoniazid and rifampicin) (Caminero et al., 2006). Extensively
drug-resistant (XDR) tuberculosis (TB) strains are resistant to
isoniazid or rifampicin (like MDR-TB), any fluoroquinolone, and
at least one of three second-line injectable antituberculosis drugs
(i.e., capreomycin, kanamycin, and amikacin) (Caminero et al.,
2010). MDR and XDR-TB are generally thought to have high
mortality rates. Treatment is challenging because of the high tox-
icity of second-line drugs and the longer treatment duration that
participates to reduce the choice of available therapy. In a recent
series of patients with XDR-TB, 58% experienced drug-associated
adverse events including 9% lethal; therapy was discontinued in
28% (Shean et al., 2013). Right combination and rational use of
available and safe antituberculosis drugs is therefore challenging
(Mitnick et al., 2008). However, standardized strategies including
pretreatment counseling, and follow-up are essential prerequisites
in view to optimize therapy.
Here, we evaluated the clinical efficacy of 2 drugs belonging to
group five in the World Health Organization (WHO) guidelines
on MDR-TB treatment (i.e., clofazimine and amoxicillinie with
clavulanate) and 2 antibiotics that are not listed but that may be
candidates for evaluation againstMycobacterium tuberculosis (i.e.,
TMP/SMX and minocycline).
CLOFAZIMINE
Clofazimine, a lipophilic riminophenazine antibiotic, was first
synthesized in 1954 by Barry et al. as an anti-tuberculosis drug
(Barry et al., 1957) but has known extended clinical use in
the early 1970s to fight the emergence of Mycobacterium leprae
resistant to sulfones.
In a report from Bangladesh, regimens containing clofazimine
showed high efficacy (87.9% cure rate) in the treatment of MDR-
TB (Van Deun et al., 2010). In a Korean study, 32 patients with
MDR-TB and additional resistance to ofloxacin (11 with XDR-
TB) were treated with clofazimine-containing regimens, with
a lower cure rate (48.4%) (Yoo et al., 2013). Another recent
report showed a cure rate of 38.4% with combination regimens
including clofazimine for the treatment of MDR-TB, with mild
adverse events (Xu et al., 2012). Adequate dose management
would help to control adverse events, especially photosensitivity
and gastric intolerance. Clofazimine’s low cost is an additional
advantage, although the drug is not widely available (Caminero
et al., 2010).
AMOXICILLIN WITH CLAVULANATE
Amoxicilline-clavulanate, combined with other second-line
drugs, has been successfully used to treat patients with
Table 3 | Availability from usual marketing system of the selected antibiotics in Europe, the USA, Canada and Australia (adapted from Pulcini
et al., 2012).
Molecules Countries
Colistin AT, AU, BG, CA, CH, CZ, DK, EL, ES, FI, FR, FY, HU, IE, IT, LU, LV, MT, PL, PT, RO, SK, TR, UK, US
Fosfomycin IV AT, DE, EL, ES, FR, IT
Fosfomycin PO AT, BE, BG, CA, CH, DE, ES, FR, IE, IT, LU, NL, PL, PT, RO, SK, TR, US
Mecillinam DK, EL
Pivmecillinam AT, CA, DK, FI, FR, IS, NO, PT, SE, UK, ES, LU
Temocillin BE, UK
Nitrofurantoin AL, AT, AU, BE, BG, CA, CH, DE, DK, EE, EL, ES, FI, FR, HR, HU, IE, IS, IT, LT, LU, LV, MT, NL, NO, PL, PT, RO, TR, UK,
US, XZ
Trimethoprim-sulfamethoxazole AT, AU, BE, CH, CZ, DE, DK, EL, ES, FI, FR, HU, IE, IT, LU, NL, NO, PL, PT, RO, SE, SK, UK, US
Doxycycline AT, AU, BE, CH, CZ, DE, DK, EL, ES, FI, FR, HU, IE, IT, LU, NL, NO, PL, PT, RO, SE, SK, UK, US
Minocycline AT, AU, BE, CH, CZ, DE, EL, ES, FR, IE, IT, LU, NL, PT, RO, SE, UK, US
Chloramphenicol AL, BG, CA, CZ, EL, ES, FI, IS, IT, MT, NO, PT, RS, SE, SK, TR, UK, US, XZ
Clindamycin AT, AU, CH, DE, DK, EL, ES, FI, FR, HU, IE, IT, LU, NL, NO, PL, PT, RO, SE, SK, UK, US
Pristinamycin FR, LU
Clofazimine AU, CH, CZ, EL, ES, IE, FR, NL, US, UK
AL, Albania; AT, Austria; AU, Australia; BE, Belgium; BG, Bulgaria; CA, Canada; CH, Switzerland; CZ, Czech Republic; DE, Germany; DK, Denmark; EE, Estonia; EL,
Greece; ES, Spain; FI, Finland; FR, France; FY, Republic of Macedonia; HR, Croatia; HU, Hungary; IE, Ireland; IS, Iceland; IT, Italy; LT, Lithuania; LU, Luxembourg; LV,
Latvia; MT, Malta; NL, Netherlands; NO, Norway; PL, Poland; PT, Portugal; RO, Romania; RS, Serbia; SE, Sweden; SI, Slovenia; SK, Slovakia; TR, Turkey; UK, United
Kingdom; US, United States; XZ, Kosovo; IV, Intra-venous; PO, Per os.
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy October 2014 | Volume 5 | Article 551 | 8
Cassir et al. The revival of old antibiotics
MDR-tuberculosis (Nadler et al., 1991; Mitnick et al., 2008). The
good tolerability, low price, and low toxicity profile of this drug
have made it the drug of choice within group five according to the
WHO guidelines for MDR-TB treatment (Caminero et al., 2006).
TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP/SMX)
Between the late 1930s and the early 1950s, sulfonamides were
used, usually as a monotherapy, for the treatment of tuberculosis.
Because of the toxicity of the early sulfonamides and the introduc-
tion of highly effective anti-tuberculosis drugs such as isoniazid
and streptomycin, both groups of drugs were abandoned for the
treatment of tuberculosis in the early 1950s, and their use was
essentially forgotten (Forgacs et al., 2009).
Clinical experience with TMP/SMX is scarce, but there is
promising evidence supporting the treatment of XDR-TB with
combination regimens (Forgacs et al., 2009; Dubourg et al., 2013).
In light of those results and the fact that MDR and XDRM. tuber-
culosis strains have been found to be susceptible in vitro to both
sulfadiazine and TMP/SMX (Ameen and Drancourt, 2013), fur-
ther clinical trials are needed to consider sulfamides as alternative
anti-tuberculosis antibiotics in combination regimens.
The great susceptibility of M. tuberculosis to TMP/SMX has
been recently confirmed and attributed to the sulfonamide com-
pound alone (Huang et al., 2012). In this study, susceptibility
to sulfamethoxazole remained constant over a 12-year period
despite the expanded use of TMP/SMX in the HIV-positive
population.
MINOCYCLINE
Minocycline activity against M. tuberculosis was first reported in
1983 (Tsukamura et al., 1983). This molecule is effective against
M. leprae and has been used in combination regimens for the
treatment of leprosy; however, minocycline was successfully used
in the rescue treatment of an XDR-TB patient in Japan (Kawada
et al., 2008). More recently, Brouqui et al. reported the first
effective treatment with a regimen including linezolid, minocy-
cline, sulfadiazine, and clofazimine according to the susceptibility
profile of a patient with XDR-TB (Brouqui et al., 2013).
CONCLUSION
In an era of increasing emergence of drug resistance and a scarcity
of new antibiotics, there is a growing need to optimize the use of
old and new antibiotics to treat infections. The arsenal of avail-
able antimicrobial drugs may be regulated by principles other
than the lack of profit for drugs in limited-market areas. Indeed,
in the last 20 years, pharmaceutical companies have developed
highly profitable drugs that treat chronic diseases (i.e., hyper-
tension, diabetes, dyslipidemia, and psychiatric disorders) rather
than new antibiotics (Spellberg et al., 2004). Most likely for the
same reasons, small countries have undergone shortages and
market withdrawals of older antibiotics (Pulcini et al., 2012).
Despite the increasing evidence of their effectiveness and safety,
the United States Food and Drug Administration (FDA) has
still not approved the use of some old antibiotics (i.e., fusidic
acid, intravenous fosfomycin, pivmecillinam, temocillin, pristi-
namycin) (Table 3) http://www.accessdata.fda.gov/scripts/cder/
drugsatfda/. As public health concern, cost effectiveness might be
integrated in further comparisons between old and currently used
antibiotics.
Optimization of antibiotic therapy in terms of pharmacoki-
netics and pharmacodynamics is needed to improve therapeutic
outcomes but minimize the toxicity and the risk of resistance
emerging during treatment (Mouton et al., 2011). Indeed, sub-
therapeutic concentrations may favor the development of resis-
tance in both the infecting pathogen and the commensal flora
(Mohamed et al., 2012). Moreover, dosage adjustments, avoid-
ance of co-administration of other toxic agents, and prompt
discontinuation after early signs of toxicity are critical for the
clinical revaluation of old antibiotics. For instance, recent stud-
ies revealed that adverse events with colistin were not as frequent
as previously reported, in part due to more accurate prescription
(Falagas and Kasiakou, 2006). Updates of old antibiotics toxicity
assessment with optimized dosing and monitoring and adapted
pharmacological studies are urgently warranted.
Finally, as old antibiotics are rarely included in surveillance
programs, data regarding resistance rates, minimal inhibitory
concentration (MIC), and harmonization are lacking (Mouton
et al., 2011). Moreover, geographic variations make the extrap-
olation of local results inaccurate (Deshpande et al., 2007). Thus,
susceptibility testing for old but effective and safe antibiotics may
be integrated into routine practice in the way to ensure antimicro-
bial resistance local surveillance. As some of these old antibiotics
(i.e., fosfomycin, TMP/SMX, clindamycin, pristinamycin, and
fusidic acid) could also favor horizontal spread of resistance, their
reuse should be associated with a global ecology survey. In this
case, combination therapy remains an alternative for their reuse.
In summary, all old antibiotics included in this review have
been associated with successful treatment of MDR bacterial infec-
tions. Their reuse represents a promising strategy to fight antimi-
crobial resistance. But some points remain critical for their revival
in a sustainable manner and need further evaluations. First, clini-
cal trials comparing the clinical, safety, and cost effectiveness with
current antibiotics are lacking. Second, prescription of old antibi-
otics needs also to be regulated by antibiotic stewardships and
guided by resistance rates monitoring. Third, optimization of the
usage of old antibiotics remains a priority that may be considered
of similar importance to that of the assessment of new drugs.
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